Fair Accountability and Innovative Research Drug Pricing Act of 2021
- Last Action
- 3/23/2021
Actions
- 2021-03-23Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2021-03-23Introduced in Senate
CRS Summary
As of 2021-03-23 (00)
Fair Accountability and Innovative Research Drug Pricing Act of 2021
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
Cosponsors (5)
- Mike Braun (R-IN)
- Tina Smith (D-MN)
- Lisa Murkowski (R-AK)
- John Hoeven (R-ND)
- Angus King (I-ME)
Subjects
- Business records
- Civil actions and liability
- Congressional oversight
- Consumer affairs
- Corporate finance and management
- Government information and archives
- Government studies and investigations
- Health care costs and insurance
- Inflation and prices
- Manufacturing
- Marketing and advertising
- Medical research
- Prescription drugs
- Research and development
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.